FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1919721665> ?p ?o ?g. }

• W1919721665 endingPage "221" @default.
• W1919721665 startingPage "215" @default.
• W1919721665 abstract "Abstract To develop efficient synergistic or additive combinations of chemopreventive and nutritional agents to reduce the risk of colon cancer, experiments were designed to test the application of a selective cyclooxygenase-2 (COX-2) inhibitor together with dietary ω-3 polyunsaturated fatty acids (PUFAs), such as decosahexaenoic acid (DHA). Thus, individual application of celecoxib, a COX-2 inhibitor, DHA, a ω-3 PUFA, and combinations of both were tested for their effectiveness using cell proliferation, apoptosis, and COX-2 expression as markers in the human colon cancer HCA-7 cell line. HCA-7 cells exposed to various subtoxic doses of celecoxib, DHA, or combinations of both were analyzed for inhibition of cell proliferation by trypan blue exclusion and proliferating cell nuclear antigen methods, induction of apoptosis by 4′,6-diamidino-2-phenylindole method, and COX-2 by reverse transcription-PCR and Western blot analysis. In addition, we examined the inhibitory potential of celecoxib and DHA on 14C-arachidonic acid metabolism mediated by COX-2 in the HCA-7 cell line. We found that treatment with celecoxib (50–150 μm) or DHA (150–225 μm) individually induces apoptosis and inhibits cell proliferation only at high concentrations in HCA-7 cell lines. A synergistic effect was observed on induction of apoptosis and inhibition of proliferation when cells were exposed to low doses of celecoxib (50–100 μm) together with DHA (75 μm). At high concentrations, celecoxib and DHA blocked the increase in COX-2 protein and mRNA expression in HCA-7 cells. Importantly, the inhibition of COX-2 expression was more pronounced in cells treated with low-dose combinations than with individual agents at high concentrations. In addition, celecoxib and DHA at low-dose levels inhibited 14C-arachidonic acid metabolism (50–85%, P &lt; 0.0001) leading to very low levels of type 2 series prostaglandin formation. These findings provide the basis for the development of combinations of low-dose regimens of a COX-2 inhibitor and ω-3 PUFAs such as DHA for the prevention and treatment of colon cancer. We are currently testing this concept in preclinical models." @default.
• W1919721665 created "2016-06-24" @default.
• W1919721665 creator A5004691943 @default.
• W1919721665 creator A5009422422 @default.
• W1919721665 creator A5012274510 @default.
• W1919721665 creator A5034368148 @default.
• W1919721665 creator A5043554628 @default.
• W1919721665 creator A5087621292 @default.
• W1919721665 date "2004-02-01" @default.
• W1919721665 modified "2023-10-09" @default.
• W1919721665 title "Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment" @default.
• W1919721665 cites W140965324 @default.
• W1919721665 cites W1963731521 @default.
• W1919721665 cites W1967132242 @default.
• W1919721665 cites W1970347121 @default.
• W1919721665 cites W1986160028 @default.
• W1919721665 cites W1987184215 @default.
• W1919721665 cites W2011756451 @default.
• W1919721665 cites W2013725424 @default.
• W1919721665 cites W2020428396 @default.
• W1919721665 cites W2027084505 @default.
• W1919721665 cites W2043707891 @default.
• W1919721665 cites W2051686420 @default.
• W1919721665 cites W2053388585 @default.
• W1919721665 cites W2053912935 @default.
• W1919721665 cites W2056935575 @default.
• W1919721665 cites W2062035543 @default.
• W1919721665 cites W2090406571 @default.
• W1919721665 cites W2105372476 @default.
• W1919721665 cites W2109694492 @default.
• W1919721665 cites W2113491538 @default.
• W1919721665 cites W2117580825 @default.
• W1919721665 cites W2119432641 @default.
• W1919721665 cites W2125644093 @default.
• W1919721665 cites W2148595234 @default.
• W1919721665 cites W2149233326 @default.
• W1919721665 cites W2156470937 @default.
• W1919721665 cites W2253276860 @default.
• W1919721665 cites W2314308884 @default.
• W1919721665 cites W2330709704 @default.
• W1919721665 cites W2336169581 @default.
• W1919721665 cites W2343388464 @default.
• W1919721665 cites W2893063334 @default.
• W1919721665 cites W2906777218 @default.
• W1919721665 cites W4211149743 @default.
• W1919721665 doi "https://doi.org/10.1158/1535-7163.215.3.2" @default.
• W1919721665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14985462" @default.
• W1919721665 hasPublicationYear "2004" @default.
• W1919721665 type Work @default.
• W1919721665 sameAs 1919721665 @default.
• W1919721665 citedByCount "62" @default.
• W1919721665 countsByYear W19197216652012 @default.
• W1919721665 countsByYear W19197216652013 @default.
• W1919721665 countsByYear W19197216652014 @default.
• W1919721665 countsByYear W19197216652015 @default.
• W1919721665 countsByYear W19197216652016 @default.
• W1919721665 countsByYear W19197216652017 @default.
• W1919721665 countsByYear W19197216652018 @default.
• W1919721665 countsByYear W19197216652019 @default.
• W1919721665 countsByYear W19197216652020 @default.
• W1919721665 countsByYear W19197216652021 @default.
• W1919721665 countsByYear W19197216652022 @default.
• W1919721665 crossrefType "journal-article" @default.
• W1919721665 hasAuthorship W1919721665A5004691943 @default.
• W1919721665 hasAuthorship W1919721665A5009422422 @default.
• W1919721665 hasAuthorship W1919721665A5012274510 @default.
• W1919721665 hasAuthorship W1919721665A5034368148 @default.
• W1919721665 hasAuthorship W1919721665A5043554628 @default.
• W1919721665 hasAuthorship W1919721665A5087621292 @default.
• W1919721665 hasBestOaLocation W19197216651 @default.
• W1919721665 hasConcept C121608353 @default.
• W1919721665 hasConcept C126322002 @default.
• W1919721665 hasConcept C181199279 @default.
• W1919721665 hasConcept C185592680 @default.
• W1919721665 hasConcept C190283241 @default.
• W1919721665 hasConcept C2776467144 @default.
• W1919721665 hasConcept C2778078955 @default.
• W1919721665 hasConcept C2779689624 @default.
• W1919721665 hasConcept C2779707156 @default.
• W1919721665 hasConcept C526805850 @default.
• W1919721665 hasConcept C54355233 @default.
• W1919721665 hasConcept C55493867 @default.
• W1919721665 hasConcept C62112901 @default.
• W1919721665 hasConcept C71924100 @default.
• W1919721665 hasConcept C81885089 @default.
• W1919721665 hasConcept C86803240 @default.
• W1919721665 hasConcept C98274493 @default.
• W1919721665 hasConceptScore W1919721665C121608353 @default.
• W1919721665 hasConceptScore W1919721665C126322002 @default.
• W1919721665 hasConceptScore W1919721665C181199279 @default.
• W1919721665 hasConceptScore W1919721665C185592680 @default.
• W1919721665 hasConceptScore W1919721665C190283241 @default.
• W1919721665 hasConceptScore W1919721665C2776467144 @default.
• W1919721665 hasConceptScore W1919721665C2778078955 @default.
• W1919721665 hasConceptScore W1919721665C2779689624 @default.
• W1919721665 hasConceptScore W1919721665C2779707156 @default.
• W1919721665 hasConceptScore W1919721665C526805850 @default.
• W1919721665 hasConceptScore W1919721665C54355233 @default.

• next